Patients with advanced melanoma experienced high response rates when treated with commercial Amtagvi in a real-world clinical ...
Anti–PD-1 therapy (pembrolizumab, nivolumab) supports neoadjuvant and adjuvant management of higher-risk melanoma, offering durable remissions with less systemic toxicity than traditional chemotherapy ...
Daniel Kirby, Chief Commercial Officer of Iovance, stated, “The real world Amtagvi data with impressive response rates, paired with unprecedented five-year durability and survival data, demonstrate a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results